Showing results (121-130 of 261) with videos related to

Sort By:
Pageof 27
Behavioral Ecology and Sociobiology|July 28, 2017
Differences in social preference between the sexes during ontogeny drive segregation in a precocial speciesMark A Whiteside, Jayden O van Horik, Ellis J G Langley, et al.
The British Journal of Dermatology|November 26, 2005
Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trialG G Krueger, R G Langley, A Y Finlay, et al.
Proceedings. Biological Sciences|March 30, 2018
Do detour tasks provide accurate assays of inhibitory control?Jayden O van Horik, Ellis J G Langley, Mark A Whiteside, et al.
Clinical Science and Molecular Medicine|March 1, 1975
Resin column perfusion with whole blood or plasma separated by the continuous flow celltrifugeM J Weston, P J Mellon, P G Langley, et al.
The Journal of Animal Ecology|March 3, 2020
Early-life learning ability predicts adult social structure, with potential implications for fitness outcomes in the wildEllis J G Langley, Jayden O van Horik, Mark A Whiteside, et al.
Dermatology and Therapy|September 24, 2022
Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3Andrew Blauvelt, Melinda Gooderham, Neal Bhatia, et al.
Lancet (London, England)|July 4, 2012
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trialKim Papp, Jennifer C Cather, Les Rosoph, et al.
Animal Cognition|September 1, 2019
Unpredictable environments enhance inhibitory control in pheasantsJayden O van Horik, Christine E Beardsworth, Philippa R Laker, et al.
The British Journal of Dermatology|June 22, 2017
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trialR G Langley, T-F Tsai, S Flavin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2019
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 yearsK Reich, A Blauvelt, A Armstrong, et al.
Pageof 27